Meru Capital Group’s Pfizer PFE Stock Holding History

Meru Capital Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-63,240	Closed	-$1.96M	–	21
2020 Q2	$1.96M	Buy	63,240 +26,561	+72%	+$902K	4.51%	9
2020 Q1	$1.14M	Buy	+36,679	New	+$1.25M	2.41%	16

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Meru Capital Group's PFE Position: Q3 2020 in Review

Meru Capital Group sold out of Pfizer (PFE) in Q3 2020, closing a stake of 63,240 shares — an estimated $1.96M sold.

Meru Capital Group first reported a position in PFE in Q1 2020 and held it in 2 quarters. The position peaked at $1.96M in Q2 2020. 2,508 funds tracked by Wall St. Rank hold PFE as of Q3 2020.

Meru Capital Group reported no remaining Pfizer position as of Q3 2020 after selling out during the quarter.
Meru Capital Group sold 63,240 Pfizer shares in Q3 2020, an estimated $1.96M.
Meru Capital Group first reported a position in Pfizer in Q1 2020 and held it in 2 quarters.
Meru Capital Group's Pfizer position peaked at $1.96M in Q2 2020.
2,508 funds tracked by Wall St. Rank held Pfizer as of Q3 2020.

Based on Meru Capital Group's 13F filing for Q3 2020, filed 13 Nov 2020.